Alcohol Use Disorder · Clinical Guide
Alcohol Use Disorder Consultation
Alcohol use disorder is simultaneously psychiatric and medical. It interacts with mood, anxiety, and sleep; it interacts with psychiatric medication; and it carries consequences for the liver, the heart, the brain, and metabolic health. A consultation here examines all of that together rather than in isolation.
Consultation is provided personally by Christian S. Monsalve, M.D., a board-certified psychiatrist, by telemedicine, available only where the physician is appropriately licensed.
What This Page Covers
This guide sets out how alcohol use disorder is assessed and treated as a medical condition, and where specialist psychiatric judgement changes the plan.
Diagnosis
What Alcohol Use Disorder Is
Alcohol use disorder is a medical diagnosis, defined by a pattern of alcohol use that produces clinically significant impairment or distress. It exists on a spectrum of severity, and the appropriate treatment differs considerably along that spectrum. It is not a moral category, and it is not a single condition with a single answer.
Assessment establishes the pattern and quantity of use, the presence and severity of tolerance and withdrawal, prior treatment history, previous withdrawal episodes and their complications, co-occurring psychiatric conditions, other substance use, medical consequences, and the patient’s own goals. Severity, rather than diagnosis alone, determines what treatment is appropriate and in what setting.
Treating this as a medical condition is not a rhetorical gesture. It means the problem can be assessed systematically, and that decisions about it belong in a clinical conversation rather than being settled by willpower or exhortation.
Indications
When a Psychiatric Consultation May Help
Much alcohol treatment is delivered without a psychiatrist, and appropriately so. A specialist psychiatric consultation adds value in particular circumstances.
Co-Occurring Symptoms
Alcohol, Mood, Anxiety and Sleep
Alcohol is frequently used to manage low mood, anxiety, or difficulty sleeping — and it frequently makes all three worse over time. Untangling cause from consequence is one of the more useful things a psychiatric consultation can do.
Alcohol reliably fragments sleep architecture even when it shortens the time taken to fall asleep, and disturbed sleep in turn worsens mood, anxiety, and cognitive function. Depressive and anxiety symptoms may be primary, may be substantially alcohol-induced, or may be both — and the distinction matters, because a depressive syndrome that resolves with sustained reduction in drinking requires a different plan from one that does not.
This does not mean psychiatric treatment should be withheld until drinking stops. Evidence supports treating co-occurring alcohol use disorder and depression concurrently, and a meta-analysis of combined cognitive-behavioural therapy and motivational interviewing found benefit for both conditions.
Pharmacology
Alcohol, Psychiatric Medications and Benzodiazepines
Alcohol interacts with much of the psychiatric formulary. The interaction that deserves the most caution is with benzodiazepines and other sedatives.
Benzodiazepines and alcohol act on overlapping systems. Taken together they compound sedation and respiratory depression, and the combination carries meaningful risk — particularly alongside opioids. At the same time, benzodiazepines remain the established treatment for medically supervised alcohol withdrawal in the appropriate setting. Both facts are true, and holding them together is precisely the clinical task.
Where a patient with alcohol use disorder is also taking a long-term benzodiazepine prescription, two interacting problems exist rather than one, and the order in which they are addressed matters. Sequencing decisions of this kind are a particular focus of this practice.
Important
Verigrate does not provide, arrange, or market home detoxification, rapid detoxification, or unsupervised benzodiazepine withdrawal. Where withdrawal management is required, the appropriate level of care is determined and the patient is directed to it.
Pharmacotherapy
Medication Treatment
Medication for alcohol use disorder is under-prescribed relative to the strength of the evidence supporting it. This is one of the clearer gaps between what is known and what is routinely offered.
A systematic review and meta-analysis of 118 randomized clinical trials including 20,976 participants found that oral naltrexone at 50 mg daily and acamprosate both reduced return to drinking, with numbers needed to treat of 18 and 11 respectively; oral naltrexone also reduced return to heavy drinking. Injectable naltrexone was associated with fewer drinking days over the treatment period. Gastrointestinal adverse effects were more common with both agents than with placebo. The authors concluded that, alongside psychosocial intervention, these findings support oral naltrexone and acamprosate as first-line pharmacotherapy.
A separate network meta-analysis and a national clinical guideline reach broadly consistent conclusions. Other agents have a smaller or less consistent evidence base and may still be reasonable in particular patients. Selection depends on treatment goal, hepatic and renal function, opioid use, prior response, adherence considerations, and the patient’s own preferences — which is why this is a prescribing decision rather than a protocol.
Note
Numbers needed to treat describe average effects across trial populations. They indicate that these medications work for a meaningful proportion of patients — not that any individual patient will or will not respond.
Goals and Behavioural Treatment
Reducing Drinking, Abstinence, and Behavioural Treatment
Abstinence is the appropriate goal for some patients and not for others. Insisting on a single goal for everyone is a reliable way to lose patients who would otherwise have improved.
Abstinence is clearly indicated in some circumstances — established alcohol-related liver disease, pregnancy, a history of complicated withdrawal or seizure, and certain medication regimens among them. In other situations a reduction in quantity and frequency is a legitimate and clinically meaningful goal, and is often the goal a patient will actually engage with. Goals can also change: patients who begin by reducing sometimes move toward abstinence, and the reverse is also true.
Psychological and behavioural treatments have randomized evidence supporting them, and a network meta-analysis of psychological interventions found benefit for abstinence outcomes. Verigrate is a psychiatric consultation practice; where structured psychotherapy or a behavioural programme is indicated, it is coordinated with an appropriate clinician or programme rather than delivered here.
Safety
Withdrawal Risk and Appropriate Level of Care
Alcohol withdrawal is one of the few withdrawal syndromes that can be fatal. Assessment of withdrawal risk, and determination of the appropriate level of care, therefore precede any discussion of reducing or stopping alcohol.
Risk assessment considers the quantity and duration of drinking, previous withdrawal episodes, any history of withdrawal seizure or delirium tremens, concurrent sedative or benzodiazepine use, medical comorbidity, and the practical support available to the patient. Some patients can safely reduce alcohol as outpatients with monitoring. Others require medically supervised withdrawal management, and a smaller number require hospital or emergency care.
Where a higher level of care is indicated, the appropriate recommendation is made and the patient is directed to it — including residential, inpatient, or emergency services where necessary.
If you are in crisis
If you are experiencing symptoms of alcohol withdrawal such as tremor, confusion, hallucinations, fever, or seizure, or if you are in immediate danger, seek emergency medical care or call 911. In the United States, the 988 Suicide & Crisis Lifeline is available by call or text. This page is educational and is not a substitute for emergency assessment.
General Medical Health
Physical and Metabolic Health
Alcohol affects the liver, the cardiovascular system, the pancreas, nutritional status, sleep, and metabolic regulation. A psychiatric consultation that ignores this is incomplete.
Relevant considerations include liver function and any evidence of alcohol-related liver disease, blood pressure, glucose and lipid measures, thiamine and other nutritional status, and sleep. These findings frequently change the treatment plan, and identified physical consequences often shift a patient’s own view of their goals more than any argument does.
Emerging Metabolic Research
Researchers have begun to examine metabolic mechanisms in alcohol use disorder. One study reported that a ketogenic diet reduced alcohol withdrawal symptoms in a small human sample and reduced alcohol intake in rodents. This is early mechanistic research. It does not support ketogenic intervention as a treatment, and emphatically does not support unsupervised dietary management of alcohol withdrawal.
Evidence Hierarchy
What the Evidence Does — and Does Not — Establish
Alcohol use disorder has an unusually good evidence base for a psychiatric condition. Distinguishing the well-established from the speculative is still worth doing.
Established Evidence
Guidelines, high-quality meta-analyses, replicated randomized evidence, and mature medical principles.
Alcohol use disorder is a medical condition with defined diagnostic criteria and a spectrum of severity. Oral naltrexone and acamprosate reduce return to drinking in randomized trials and are supported as first-line pharmacotherapy alongside psychosocial intervention. Alcohol withdrawal carries real medical risk, and benzodiazepines are the established treatment for medically supervised withdrawal. Psychological and behavioural treatments have randomized evidence supporting them.
Emerging Evidence
Promising controlled trials, or a developing clinical literature not yet mature enough to support definitive conclusions.
Reduced-drinking goals as a legitimate treatment endpoint, rather than abstinence alone, are increasingly reflected in guidelines and trial design, though the comparative literature is still developing. Concurrent treatment of alcohol use disorder and co-occurring depression has meta-analytic support, but the optimal sequencing and combination of treatments in individual patients remains an active question.
Preliminary Evidence
Small pilot studies, open-label trials, retrospective analyses, case series, and feasibility data.
Metabolic approaches to alcohol use disorder sit here. A study reporting reduced withdrawal symptoms with a ketogenic diet in a small human sample, together with supporting rodent data, represents preliminary mechanistic work. It does not establish a treatment.
Clinical Uncertainty
Active research questions, or biologically plausible hypotheses for which clinical conclusions remain unsettled.
Which patients do best with which pharmacotherapy, how long treatment should continue, how best to combine medication with behavioural treatment, and how to predict who can safely pursue reduced drinking rather than abstinence are all unresolved. Guidance from one jurisdiction does not always transfer cleanly to another, and clinical judgement continues to carry weight where the evidence is silent.
Collaboration
Coordination With Primary Care, Hepatology and Addiction Services
Alcohol use disorder is frequently managed across several clinicians. Where a patient has an existing relationship with a primary care physician, hepatologist, addiction service, or therapist, that relationship is the foundation to build on. With the patient’s authorisation, Dr. Monsalve communicates directly with treating clinicians, provides written psychiatric formulation and recommendations where useful, and returns the patient to the treating team once the consultative question has been addressed.
Clinical Perspective
A drinking figure is not the outcome that matters. What matters is whether a person can think clearly, sleep, work, remain present to the people who depend on them, and act on their own aims.
Reduction, abstinence, and medication are instruments in service of that. Treating them as ends in themselves tends to produce plans that patients abandon. Treating them as means — chosen with the patient, adjusted as circumstances change — tends to produce plans that hold.
Common Questions
Questions Patients and Physicians Ask
Do I have to want to stop drinking completely?
No. Reduced drinking is a legitimate goal for many patients. Where abstinence is clearly indicated it will be said plainly; otherwise the goal is set with you.
Does Verigrate provide detoxification or residential treatment?
No. This is outpatient specialist psychiatric consultation by telemedicine. Withdrawal risk is assessed, and where a higher level of care is indicated you are directed to it.
Is medication for alcohol use disorder addictive?
The first-line agents supported by randomized evidence — naltrexone and acamprosate — are not controlled substances and are not associated with dependence. Both have side effects, most commonly gastrointestinal, which are discussed before starting.
I take a benzodiazepine and also drink. Can you help with both?
Yes — this combination is a particular focus of this practice. Assessment establishes which problem requires attention first, and in what setting. Neither should be altered abruptly.
Will my other physicians be told?
Only with your authorisation. Where you consent, direct physician-to-physician communication is often useful, particularly where liver function, medication interactions, or prescribing decisions are involved.
References
Selected Clinical References
A selection of the primary literature informing this page, ordered approximately by strength of evidence.
Systematic review and meta-analysis of 118 randomized clinical trials · JAMA, 2023 · doi:10.1001/jama.2023.19761
National clinical practice guideline (Canada) · CMAJ, 2023 · doi:10.1503/cmaj.230715
Systematic review and network meta-analysis · Journal of Addiction Medicine · doi:10.1097/ADM.0000000000000992
Systematic review and network meta-analysis · Neuropsychiatric Disease and Treatment · doi:10.2147/NDT.S372300
Meta-analysis of randomized controlled trials · Addiction · doi:10.1111/add.12441
Preliminary mechanistic study — small human sample with supporting rodent data · Science Advances, 2021 · doi:10.1126/sciadv.abf6780
Authored and medically reviewed by Christian S. Monsalve, M.D. — Board-Certified Psychiatrist, Founder & Medical Director, Verigrate Health.
This page reflects a physician-developed synthesis of contemporary guidelines and peer-reviewed evidence concerning the assessment and treatment of alcohol use disorder. Guidance developed in one jurisdiction may not transfer directly to another, and clinical decisions remain individual.
This content is provided for educational purposes only and does not replace individualized medical evaluation or treatment. Alcohol withdrawal can be medically dangerous; do not reduce or stop alcohol without medical advice. If you are experiencing withdrawal symptoms or are in immediate danger, seek emergency care.
Clinical Summary
Alcohol use disorder responds to treatment more reliably than its reputation suggests — provided the diagnosis is accurate, the goal is agreed, the pharmacology is used properly, and withdrawal risk is taken seriously.
If previous treatment has not worked and the reason is unclear, a focused consultation is a reasonable place to begin. Care is available by telemedicine only where Dr. Monsalve is appropriately licensed.